Andrew Witty

GSK will no longer pay doctors for promoting its products

GlaxoSmithKlineBritish drug maker GlaxoSmithKline (GSK) has decided to put an end to two very common controversial industry practices - paying doctors to promote the company's products and tying sales representatives' compensation to the number of prescriptions doctors write.

GSK Chief Executive Andrew Witty confirmed on Tuesday that the company would stop paying doctors for promoting its products and also stop tying representative's compensation to number of prescriptions doctors write.

Glaxo’s sales fall 61% in China

GlaxoPharmaceutical giant, Glaxo has said that it sales has fallen by a disappointing 61 per cent in China during the third quarter as the company faces a massive investigation into bribery in the country.

Britain's biggest drugmaker's business has been impacted due to the ongoing investigation into its business by the authorities in China. The crisis in China affected its turnover to be below market expectations at £6,610 million. The company's third quarter core earnings per share (EPS) was recorded at 28.9p and the company expects the EPS to grow around 3-4 per cent on a constant exchange rates basis.

Three GSK top officials in China to tackle bribery case

Three GSK top officials in China to tackle bribery caseThree senior level management officials of GlaxoSmithKline are now in China to prepare a response to the allegations of bribery and corruption in the country.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content